Just a few neoantigens may be enough for T cells to control prostate cancer

In a phase II clinical trial, 29 patients with metastatic castration-resistant prostate cancer were treated with ipilimumab after tumor resection. Median radiographic PFS was 3 months, median clinical PFS was 2 months, and median OS was 24 months. Best ORR was stable disease in 37% of patients. In the “favorable” cohort (PFS>6 months, median OS of 45 months), pretreatment tumors had increased CD8+ T cell density and IFNγ response gene signature compared with the “unfavorable” cohort (PFS<6 months, median OS of 5 months), while TMB was similar between cohorts. In post-treatment PBMCs, CD8+ T cell responses to PSMA, PAP, and/or neoantigens were found in 4 patients, all of which were in the favorable cohort.

Making the cut: exitrons as a new source of neoantigens

Frontiers T Cell Dysfunction and Exhaustion in Cancer

Uro, Free Full-Text

Frontiers Fundamentals of T Cell Metabolism and Strategies to

Targeting public neoantigens for cancer immunotherapy. - Abstract

Neoantigens: promising targets for cancer therapy

Cancers, Free Full-Text

Frontiers Neoantigens and NK Cells: “Trick or Treat” the Cancers?

A primer on recent developments in cancer immunotherapy, with a

Developing neoantigen-targeted T cell–based treatments for solid

Biological bases of cancer immunotherapy

Neoantigen responses, immune correlates, and favorable outcomes